Search results
Showing 61 to 75 of 103 results for schizophrenia
organisations. 2002 First clinical guideline CG1 Schizophrenia (December). Read more about guidelines The National Guidelines and
this is important:- The personal and financial cost of psychosis and schizophrenia to the person, their family and friends, and to...
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance....
View recommendations for HTE15Show all sections
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people....
View recommendations for HTE17Show all sections
This quality standard covers identifying and managing anxiety disorders in adults, young people and children in primary, secondary and community care. It covers a range of anxiety disorders, including generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive-compulsive disorder and body dysmorphic disorder. It describes high-quality care in priority areas for improvement.
This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause of behaviour that challenges, and performing thorough assessments so that steps can be taken to help people change their behaviour and improve their quality of life. The guideline also covers support and intervention for family members or carers.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
morbidity and premature mortality in young people with psychosis and schizophrenia. Most evidence of adverse effects comes from...
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.
TA037 Rituximab for follicular lymphoma 21 May 2001 TA043 Schizophrenia - Atypical antipsychotic 24 April 2002 TA397 Systemic lupus...
Learning disability: identifying and managing mental health problems (QS142)
This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.
View quality statements for QS142Show all sections
Sections for QS142
- Quality statements
- Quality statement 1: Annual health check
- Quality statement 2: Assessment by a professional with relevant expertise
- Quality statement 3: Key worker
- Quality statement 4: Tailoring psychological interventions
- Quality statement 5: Annually documenting the reasons for continuing antipsychotic drugs
- About this quality standard
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Multiple long-term conditions: multimorbidity register (IND205)
This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184
antipsychotic medicines recommended in the NICE guidelines on psychosis and schizophrenia in adults and bipolar disorder should form the...
Source guidance details Comes from guidance Psychosis and schizophrenia in children and young people: recognition and management Number